Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Artemis II shares new lunar images while more than halfway to the moon - 2Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- 3Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- 4PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- 5More charges filed against ex-left-wing RAF member Daniela Klette
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- Defense Minister Katz moves to extend IDF service to 36 months
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Central African Republic's president sworn in for a third term after disputed election
- Web designers for Independent ventures
- New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
